Answers are grounded in this paper and cite their sources.
The investigated biologics demonstrated improved efficacy and QoL relative to placebo at week 28, with no increased risk of SAEs vs. placebo through week 16. At week 28, efficacy of tildrakizumab, risankizumab, and guselkumab was comparable. Limitations include lack of placebo comparators after week 12 or 16, which could affect results.
No takes yet. Share an insight, caveat, or question.
Lebwohl et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: